Atlas Trials

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Clinical trial NCT03339778 · COMPLETED

Trial details

NCT number
NCT03339778
Sponsor
IMMUNOe Research Centers
Status
COMPLETED
Study type
OBSERVATIONAL
Primary Immunodeficiency
Start date
2015-06-01
Primary completion
2016-11-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.